CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 101 enrolled
Drug / intervention
Blood sample collectionother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04767750
NCT04767750N/ACompleted

Role of LncRNA H19 in The Regulation of IGF-1R Expression: A Possible Association Between Type 2 Diabetes and Hepatocellular Carcinoma

Mansoura University·observational·Posted Feb 23, 2021·Updated Apr 7, 2022

In Brief

An observational study evaluating Blood sample collection for Hepatocellular Carcinoma and 2 related conditions. Completed, enrolled 101 participants across 2 sites.

Detailed Summary

Hepatocellular carcinoma (HCC) is a common cancer that poses a heavy economic burden on the healthcare system. In Egypt, it is the most common cause of mortality and morbidity-related cancer. Diabetes mellitus (DM) is a metabolic disorder characterized by hyperglycemia. Cancer and type II diabetes (T2DM), the world's two most prevalent diseases, share many overlapping risk factors and predisposing pathological conditions. The exact mechanisms linking those two diseases are yet to be fully understood. In this study, the investigators aim to assess the relationship between Long Non-Coding RNA (lncRNA) H19 and Insulin-Like Growth Factor 1 Receptor (IGF-1R) mRNA gene expressions in the blood samples of HCC \& T2DM patients to investigate the probability of the presence of a pathophysiological link between HCC and DM that may become a therapeutic target for both diseases. To the investigator's knowledge, there is currently no human research study investigating both H19 and IGF-1R in both DM and cancer.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesEgypt
Collaborators--

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedFeb 23, 2021
Enrollment StartJan 1, 2020
Primary CompletionJan 30, 2022
Study CompletionApr 4, 2022
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 5.4 years ago

Interventions

Blood sample collectionother

5ml of peripheral blood samples will be collected into tubes containing EDTA from all subjects and the following procedures will be performed: * Peripheral blood mononuclear cells (PBMCs) will be isolated from blood samples. * Total RNA extraction from PBMCs by Trizol reagent and spin column. * Reverse transcription to cDNA. * The expression levels of lncRNA H19, IGF-1R mRNA and GAPDH gene (control gene) will be determined by Real-Time Quantitative PCR